**12-12-2012: MSK Researchers Jedd Wolchok & Michel Sadelain Appointed to “Stand Up To Cancer” Immunology “Dream Team” TWO APPROACHES TO ATTACKING CANCER: The Immunology Dream Team will pursue 2 research techniques. The 1st, being led by Dr. Wolchok, involves studying how a type of white blood cell called a T lymphocyte, or T cell, can kill cancer cells. Sometimes, the natural function of the T lymphocyte is blocked or not activated enough to attack cancer cells, allowing the cancer to grow. Part of the Dream Team’s focus will be to investigate ways to ensure that the T lymphocytes work properly in recognizing and killing cancer cells. The 2nd immunotherapy approach, known as Adoptive Cell Transfer (ACT), involves removing some of a patient’s T cells, enhancing their cancer-fighting abilities and growing them in the laboratory, and then infusing the enhanced cells back into the patient. This can provide a patient with an army of immune cells specifically programmed to fight against cancer. This part of the Dream Team’s research, led by Dr. Sadelain, will investigate several ways to use ACT as a cancer therapy. https://www.mskcc.org/blog/msk-researchers-appointed-stand-immunology-dream-team
Much more coming from CAR-T / Adoptive Cell Transfer in Feb 2018 and we have Jerome Galon (Immunoscore) and many more...and will list the full lineup in case any changes but first we should be reminded of Jerome Galon
..... ..... In an effort to promote the Immunoscore in routine clinicalsettings, a worldwide task force was initiated by Dr Galon.
The working group composed of international expert pathologists and immunologists identified a strategy for the organization of a worldwide participation by various groups for the validation of the Immunoscore .. ... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135970680
Emerging Cellular Therapies: T Cells and Beyond (B6) joint with the meeting on Lymphocytes and their Roles in Cancer (R1)
Scientific Organizers: Carl H. June, Marcela V. Maus and Bruce R. Blazar
February 11—15, 2018 Keystone Resort, Keystone, Colorado, USA
Sponsored by BioLegend, Inc., Editas Medicine, Gilead Sciences, Inc., Juno Therapeutics, Regeneron Pharmaceuticals, Inc., Sangamo Therapeutics, Inc. and Takeda Pharmaceutical Company Limited
Abstract submission is now closed. Registered attendees may bring a poster onsite. Please contact our office at +1 800-253-0685; +1 970-262-1230 or email info@keystonesymposia.org if you are interested. BEWARE of booking lodging through companies unaffiliated with Keystone Symposia. Click here for more details.
Keystone Symposia is committed to maintaining a positive and respectful environment at its meetings. To this end, please review and comply with our policies.
Registered attendees of one meeting in a joint pair may participate in sessions of the other, pending space availability.
DEADLINES: Scholarship Deadline: Oct 11, 2017 [details] Discounted Abstract Deadline: Oct 11, 2017 [details] Abstract Deadline: Nov 9, 2017 [details] Discounted Registration Deadline: Dec 13, 2017 [details]
Click here to view Cancellation Policy
Register Yourself Deadlines and Fees
No registration fees are used to fund entertainment or alcohol at this conference
Conference Program Print | View meeting in 12 hr (am/pm) time
The meeting will begin on Sunday, February 11 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, February 15 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, February 16 in order to fully experience the meeting.
SUNDAY, FEBRUARY 11
16:00—20:00 Arrival and Registration
Longs Peak Foyer 18:00—20:00 Welcome Mixer No registration fees are used to fund alcohol served at this function.
Longs Peak Foyer
MONDAY, FEBRUARY 12
07:00—08:00 Breakfast
Colorado Rockies Ballroom 08:00—09:00 Welcome and Keynote Address Registered attendees can view abstracts starting on 01/11/2018
Grays/Longs Peak Ton N. Schumacher, Netherlands Cancer Institute, Netherlands T Cell Recognition in Human Cancer
Following Session is for Lymphocytes and their Roles in Cancer (R1)
08:00—09:00 Welcome and Keynote Address Registered attendees can view abstracts starting on 01/11/2018
Quandary Peak * Iannis Aifantis, New York University School of Medicine, USA
Alexander Y. Rudensky, HHMI, Memorial Sloan Kettering Cancer Center, USA Regulatory T Cells and their Functions in the Tumor Microenvironment
09:00—11:15 CAR/TCR Preclinical Registered attendees can view abstracts starting on 01/11/2018
Grays/Longs Peak Philip D. Greenberg, University of Washington, USA Making TCR-Modified T Cells Effective for Leukemia and Solid Tumors
Coffee Break
Crystal L. Mackall, Stanford University, USA CAR T Cells in Pediatric Malignancies
Stanley R. Riddell, Fred Hutchinson Cancer Research Center, University of Washington, USA Strategies to Improve the Efficacy of CAR T Cells in Solid Tumors
Short Talk(s) Chosen from Abstracts
Following Session is for Lymphocytes and their Roles in Cancer (R1)
09:00—11:15 Understanding Lymphocytic Malignancy: Leukemia and Lymphoma Registered attendees can view abstracts starting on 01/11/2018
Quandary Peak * Adolfo Ferrando, Columbia University, USA
Louis M. Staudt, NCI, National Institutes of Health, USA The MYD88-TLR9-B Cell Receptor Complex as a Target for Therapy in Aggressive Lymphomas
Coffee Break
Charles G. Mullighan, St. Jude Children's Research Hospital, USA Biology of Relapse in Acute Lymphoblastic Leukemia
Katia Georgopoulos, Massachusetts General Hospital, USA Early Events in Lymphocytic Differentiation and Transformation
Anastasia N. Tikhonova†, New York University Medical School, USA Short Talk: Single-Cell Dynamics of Bone Marrow Microenvironment
Colorado Rockies Ballroom 14:30—16:30 Workshop 1: Perspectives from Industry and FDA: Roundtable
Grays/Longs Peak Short Talks Chosen from Abstracts
Following Session is for Lymphocytes and their Roles in Cancer (R1)
14:30—16:30 Workshop 1: Understanding and Targeting Lymphocytes in Cancer
Quandary Peak * Iannis Aifantis, New York University School of Medicine, USA
Eirini Giannakopouou, Radiumhospitalet, Norway T Cell Receptor-Mediated Targeting Of Recurrent Neoantigens In Acute Myeloid Leukemia
Wenting Zheng, St. Jude Children Research Hospital, USA PI3K Orchestration of the in vivo Persistence of Chimeric Antigen Receptor-Modified T Cells
Elena Montauti, Northwestern University, USA USP22 Maintains Regulatory T cells by Stabilizing Foxp3 Protein Level and Impairs Anti-Tumor Immune Response
Jeffrey Ward, Washington University School of Medicine, USA Remodeling of Myeloid as Well as Lymphoid Compartments Following Checkpoint Blockade Immunotherapy
Soki Kashima, Kyoto University, Japan WT1-Specific Cytotoxic T Lymphocytes Regenerated from T Cell-Derived iPS Cells Exert Therapeutic Effect in Xenograft Model of Renal Cell Carcinoma
Chris Nicolai, University of California, Berkeley, USA Mechanisms of MHC-Deficient Tumor Clearance using STING Agonists
Julie A. Rytlewski, Adaptive Biotechnologies, USA History of Prior Immunotherapy Changes Relationship between Tumor Mutations and TIL Repertoire
Angela Vasaturo†, INSERM, UMRS1138, France Unravelling the Immune Contexture of Pre-Invasive Lesions of the Lung by Multispectral Imaging
16:30—17:00 Coffee Available
Longs Peak Foyer 17:00—19:00 Synthetic Biology Registered attendees can view abstracts starting on 01/11/2018
Grays/Longs Peak Darrell J. Irvine, Massachusetts Institute of Technology, USA Chemically engineering T cell therapies
Wendell A. Lim, University of California, San Francisco, USA Optimizing Synthetic Biology Tools for T Cell Therapies
Travis Young, California Institute for Biomedical Research, USA Controllable CAR-T Cell Therapy
Short Talk Chosen from Abstracts
Following Session is for Lymphocytes and their Roles in Cancer (R1)
17:00—19:00 Therapeutic Targeting of Lymphocytic Malignancy Registered attendees can view abstracts starting on 01/11/2018
Quandary Peak * Charles G. Mullighan, St. Jude Children's Research Hospital, USA
Irene M. Ghobrial, Dana-Farber Cancer Institute, USA Targeting the Tumor Microenvironment in Multiple Myeloma
Adolfo Ferrando, Columbia University, USA Epigenetic Mechanisms in T-Cell Acute Lymphoblastic Leukemia
Iannis Aifantis, New York University School of Medicine, USA Targeting Stress Responses in Acute Lymphocytic Leukemia
Jacques G. M. Ghysdael, Institut Curie, France Short Talk: Triggering the Tcr Developmental Checkpoint Activates a Therapeutically Targetable Anti-Leukemic Pathway in T-Cell Acute Lymphoblastic Leukemia
19:00—20:00 Social Hour with Lite Bites No registration fees are used to fund alcohol served at this function.
Following Session is for Lymphocytes and their Roles in Cancer (R1)
08:00—11:00 Cellular Therapies in Blood Malignancies and Beyond Registered attendees can view abstracts starting on 01/11/2018
Quandary Peak * Ugur Sahin, TRON – Translationale Oncology, Germany
Carl H. June, University of Pennsylvania, USA CAR T Cells and their Therapeutic Promise in the Treatment of Leukemia
Crystal L. Mackall, Stanford University, USA Recent Updates of Chimeric Antigen Receptor Clinical Trials
Coffee Break
Chiara Bonini, Vita Salute San Raffaele University, Italy Gene Editing of Memory Stem T Cells for Cancer Immunotherapy
Michel Sadelain, Memorial Sloan Kettering Cancer Center, USA Next Generation CAR-T Cell-Expressing Vectors and in vivo Utilization
Charlotte Mousset†, Radboudumc, Netherlands Short Talk: Superior Multi-Functionality and Glycolytic Function of Tumor-Reactive CD8+ TSCM-like T Cells by ex vivo Akt-Inhibition
08:00—11:00 Engineered T Cells for HIV Registered attendees can view abstracts starting on 01/11/2018
Grays/Longs Peak Catherine M. Bollard, Children’s National Health System, USA Developing HIV-specific T Cell Therapies: Lessons from EBV
Paula M. Cannon, University of Southern California, Keck School of Medicine, USA Shutting the Door on HIV by Engineering Hematopoietic Stem Cells
Coffee Break
James L. Riley, University of Pennsylvania, USA Engineering T Cells to Functionally Cure HIV-1 Infection
Colorado Rockies Ballroom 16:30—17:00 Coffee Available
Longs Peak Foyer 17:00—19:00 CAR/TCR in the Clinic for Cancer Registered attendees can view abstracts starting on 01/11/2018
Grays/Longs Peak Stephen J. Forman, City of Hope, USA CAR Trials in the Clinic
Marcela V. Maus, Harvard Medical School, USA CAR T Cells Multiple Myeloma and Glioblastoma
Saar I. Gill, University of Pennsylvania, USA CAR T Cells for Acute Myelogenous Leukemia
Short Talk Chosen from Abstracts
Following Session is for Lymphocytes and their Roles in Cancer (R1)
17:00—19:00 Lymphocytes as Elements of the Tumor Microenvironment Registered attendees can view abstracts starting on 01/11/2018
Quandary Peak * Katia Georgopoulos, Massachusetts General Hospital, USA
David H. Raulet, University of California, Berkeley, USA Immune Surveillance of Cancer Cells by Natural Killer Cells
Michael Kalos, Eli Lilly and Company, USA T Cells in the Microenvironment: Conductors, First Violin, or Part of the Orchestra?
Lisa M. Coussens, Oregon Health & Science University, USA Dynamic Interactions Between Myeloid and Lymphoid cells Regulate Response to Therapy in Solid Tumors
Annelise Snyder, University of Washington, USA Short Talk: Anti-tumor Effects of Inflammatory Necroptosis Within the Tumor Microenvironment
19:00—20:00 Social Hour with Lite Bites No registration fees are used to fund alcohol served at this function.
Colorado Rockies Ballroom 08:00—11:00 Tregs as Cellular Therapeutics Registered attendees can view abstracts starting on 01/11/2018
Grays/Longs Peak Bruce R. Blazar, University of Minnesota, USA Vimentin Restrains Regulatory T-cell Suppression of Graft-versus-Host Disease
Jeffrey A. Bluestone, University of California, San Francisco, USA Manipulating Tregs to Control Tolerance in Autoimmunity and Cancer
Coffee Break
Megan K. Levings, University of British Columbia, Canada HLA-A2 Directed CAR Tregs
Laurence A. Turka, Massachusetts General Hospital, USA Alloantigen-specifc Tregs for Solid Organ Transplantation
Short Talk(s) Chosen from Abstracts
Following Session is for Lymphocytes and their Roles in Cancer (R1)
08:00—11:15 Emerging Technologies: Visualization and Dissection of the Tumor Microenvironment Registered attendees can view abstracts starting on 01/11/2018
Quandary Peak * Mikala Egeblad, Cold Spring Harbor Laboratory, USA
Dana Pe'er, Memorial Sloan Kettering Cancer Center, USA A Single Cell Approach to Understanding the Tumor Microenvironment
Matthew F. Krummel, University of California, San Francisco, USA Imaging a World Beyond Checkpoints: Innate Partners for Lymphocytes in Cancer
Coffee Break
Jerome Galon, INSERM U872, Cordeliers Research Center, France Immunoscore as a Stronger Predictor of Patient Survival in Colorectal Cancer
Michael Goldberg, Dana-Farber Cancer Institute, USA Enhancing Cancer Immunotherapy through Immuno-engineering
Ashley M. Laughney, Memorial Sloan Kettering Cancer Center, USA Short Talk: Dissecting Tumor Cell Plasticity and Population Interactions Supporting Metastasis using Single Cell Genomics
Colorado Rockies Ballroom 08:00—11:00 Beyond T Cells: HSC, T Progenitor, and IPSCs II Registered attendees can view abstracts starting on 01/11/2018
Grays/Longs Peak Juan Carlos Zúñiga-Pflücker, Sunnybrook Research Institute, Canada Generation of Human Progenitor T Cells from Stem Cells
Michel Sadelain, Memorial Sloan Kettering Cancer Center, USA iPS-Derived Genetically-Modified T Cells
Coffee Break
Jakub Tolar, University of Minnesota, USA Gene Edited Stem Cells: From Cloning to Clinic
Speaker to be Announced
Short Talk(s) Chosen from Abstracts
Following Session is for Lymphocytes and their Roles in Cancer (R1)
08:00—11:00 Combinatorial Treatments and their Effects on Lymphocyte Function in Cancer Registered attendees can view abstracts starting on 01/11/2018
Quandary Peak * Ashley M. Laughney, Memorial Sloan Kettering Cancer Center, USA
David G. DeNardo, Washington University Medical School, USA The Pancreatic Tumor Microenvironment; Modulator of Tumor Progression and Response to Therapy
Dimitris Skokos, Regeneron Pharmaceuticals, USA T Cell Dysfunction and Combination Immunotherapy
Coffee Break
Michael A. Curran, University of Texas MD Anderson Cancer Center, USA Optimizing T Cell Frequency and Function via Checkpoint Antibody / Vaccine Combinations
Sjoerd H. van der Burg, Leiden University Medical Center, Netherlands Combination Treatments to Modulate the Microenvironment and Boost Tumor-specific T cells
Yuliya Pylayeva-Gupta, University of North Carolina at Chapel Hill, USA Short Talk: IL-35+ B Cells Establish Immunosuppressive Network in Pancreatic Ductal Adenocarcinoma
11:00—17:00 On Own for Lunch
16:30—17:00 Coffee Available
Longs Peak Foyer 17:00—18:45 Intersection of Genetic Editing and Cellular Therapy Registered attendees can view abstracts starting on 01/11/2018
Grays/Longs Peak Alex Marson, University of California, San Francisco, USA Reprogramming Human T Cell Circuitry
Andrew M. Scharenberg, Casebia Therapeutics, USA Editing T-Cells for Adoptive Therapy of Inflammatory Disorders
Carl H. June, University of Pennsylvania, USA Adoptive Transfer with Genetically Edited T Cells
Following Session is for Lymphocytes and their Roles in Cancer (R1)
17:00—18:45 Future Directions for Next Generation Sequencing: Genomics, Epigenetics and Immunogenomics Registered attendees can view abstracts starting on 01/11/2018
Quandary Peak * Iannis Aifantis, New York University School of Medicine, USA
Mikala Egeblad, Cold Spring Harbor Laboratory, USA Visualization of the Switch from Immune Control to Immune Escape
Mickey Atwal, Cold Spring Harbor Laboratory, USA High Throughput Profiling of T Cell Receptor Sequences in Cancer Immunotherapy
Manel Esteller, Belvitge Biomedical Research Institute (IDIBELL), Spain Cancer Epigenetics: From Knowlegde to Applications
18:45—19:00 Meeting Wrap-Up: Outcomes and Future Directions (Organizers) Registered attendees can view abstracts starting on 01/11/2018
Grays/Longs Peak
Following Session is for Lymphocytes and their Roles in Cancer (R1)
18:45—19:00 Meeting Wrap-Up: Outcomes and Future Directions (Organizers) Registered attendees can view abstracts starting on 01/11/2018
Quandary Peak 19:00—20:00 Social Hour with Lite Bites No registration fees are used to fund alcohol served at this function.
Colorado Rockies Ballroom 20:00—23:00 Entertainment Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
Colorado Rockies Ballroom
FRIDAY, FEBRUARY 16
Departure
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
Directors' Fund
These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.
Click here to view all of the donors who support the Directors' Fund.
Keystone Symposia thanks our Sponsors for generously supporting this meeting: BioLegend, Inc. Editas Medicine Gilead Sciences, Inc. Juno Therapeutics Regeneron Pharmaceuticals, Inc. Sangamo Therapeutics, Inc. Takeda Pharmaceutical Company Limited
AI
Market Data 
Markets 
